Otsuka Pharmaceutical Company, Limited

Nitto-denko Corporation

Masataka Ueda

Kuninori Tai

Hokuto Yamabe

Shuuji Matsumura

Takashi Oshiyama

Kunio Oshima

Yasuhiro Menjo

Shinichi Taira

Yasuo Koga

Noriaki Takemura

Motohiro Itotani

Toshiyuki Onogawa

Kenji Tsujimae

Sunao Nakayama

Hisanari Onouchi

Tatsuya Kitahara

Naohiro Isono

Tsuyoshi Nagase

A wavelength-converting encapsulant composition is provided, which includes a first organic material capable of absorbing ultraviolet light and converting absorbed light to longer wavelength light; and a second organic material capable of absorbing light with a wavelength longer than that of the light absorbed by the first organic material and converting absorbed light to longer wavelength light, wherein the maximum emission wavelength &#x3bb;of the first organic material and the maximum excitation wavelength &#x3bb;of the second organic material satisfy the relationship of formula (1): &#x3bb;&#x2212;60&#x2264;&#x3bb;(nm), and which has high durability, is advantageous in terms of cost and suitable for use on solar cells, and can improve the photoelectric conversion efficiency of solar cells by converting light in a wavelength region not contributable to power generation to light in another wavelength region contributable to power generation.

Wavelength-conversion encapsulant composition, wavelength-converted encapsulant layer, and solar cell module using same

The present invention provides a novel diazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The present invention relates to a diazepine compound represented by General Formula (1)  

Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation

The present invention provides a novel benzodiazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound of the invention is represented by General Formula (1) wherein R, R, R, and Rare each independently hydrogen or lower alkyl; Rand Rmay be linked to form lower alkylene; wherein Rand Rare each independently hydrogen or organic group;

Benzodiazepine compound and pharmaceutical composition

The present invention provides a novel benzodiazepine compound that blocks the Icurrent or the Kv1.5 channel potently and more selectively than other Kchannels. The benzodiazepine compound of the invention is represented by General Formula (1)  

Growing community of inventors

Osaka, Japan

Masataka Ueda